See more : Vertu Motors plc (VTU.L) Income Statement Analysis – Financial Results
Complete financial analysis of Genetron Holdings Limited (GTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genetron Holdings Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Fushun Special Steel Co.,LTD. (600399.SS) Income Statement Analysis – Financial Results
- Euronext N.V. (EUXTF) Income Statement Analysis – Financial Results
- Storage Drop Storage Technologies Ltd (STRG.TA) Income Statement Analysis – Financial Results
- Solar Enertech Corp. (SOEN) Income Statement Analysis – Financial Results
- Nasdaq BRIC Consumer Staples In (KEIL.BO) Income Statement Analysis – Financial Results
Genetron Holdings Limited (GTH)
About Genetron Holdings Limited
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 650.71M | 531.95M | 424.49M | 323.43M | 225.18M | 101.03M |
| Cost of Revenue | 369.28M | 193.98M | 164.27M | 178.44M | 132.45M | 74.21M |
| Gross Profit | 281.43M | 337.97M | 260.22M | 144.99M | 92.73M | 26.82M |
| Gross Profit Ratio | 43.25% | 63.53% | 61.30% | 44.83% | 41.18% | 26.55% |
| Research & Development | 290.29M | 253.95M | 149.00M | 91.70M | 71.41M | 45.78M |
| General & Administrative | 266.91M | 227.00M | 126.32M | 117.17M | 88.23M | 45.49M |
| Selling & Marketing | 364.56M | 343.16M | 246.96M | 253.56M | 182.47M | 94.57M |
| SG&A | 631.47M | 570.16M | 373.28M | 370.73M | 270.71M | 140.06M |
| Other Expenses | -8.71M | -5.33M | -8.53M | -10.85M | -233.63M | -258.11M |
| Operating Expenses | 913.05M | 818.78M | 513.75M | 451.58M | 332.19M | 181.01M |
| Cost & Expenses | 1.28B | 1.01B | 678.02M | 630.01M | 464.64M | 255.22M |
| Interest Income | 2.86M | 20.50M | 28.33M | 441.00K | 1.55M | 513.00K |
| Interest Expense | 111.49M | 5.25M | 5.63M | 5.40M | 0.00 | 669.00K |
| Depreciation & Amortization | 85.39M | 20.50M | -2.80B | -319.22M | 27.86M | 20.61M |
| EBITDA | -651.24M | -460.32M | -201.69M | -625.81M | -212.21M | -134.08M |
| EBITDA Ratio | -83.94% | -86.53% | -718.18% | -193.49% | -197.04% | -397.06% |
| Operating Income | -631.62M | -480.82M | -253.53M | -306.59M | -232.98M | -152.54M |
| Operating Income Ratio | -97.07% | -90.39% | -59.73% | -94.79% | -103.46% | -150.98% |
| Total Other Income/Expenses | -108.69M | 21.04M | -2.80B | -366.94M | -225.53M | -268.10M |
| Income Before Tax | -810.63M | -502.60M | -3.07B | -676.03M | -464.99M | -420.64M |
| Income Before Tax Ratio | -124.58% | -94.48% | -723.00% | -209.02% | -206.50% | -416.34% |
| Income Tax Expense | 73.26M | -64.19M | -2.87B | -354.54M | -232.02M | -257.44M |
| Net Income | -883.89M | -438.40M | -198.11M | -321.49M | -464.99M | -420.64M |
| Net Income Ratio | -135.84% | -82.41% | -46.67% | -99.40% | -206.50% | -416.34% |
| EPS | -9.53 | -4.76 | -3.29 | -4.65 | -6.73 | -6.22 |
| EPS Diluted | -9.53 | -4.76 | -3.29 | -4.65 | -6.73 | -6.22 |
| Weighted Avg Shares Out | 92.80M | 92.11M | 60.28M | 69.07M | 69.07M | 67.68M |
| Weighted Avg Shares Out (Dil) | 92.80M | 92.11M | 60.28M | 69.07M | 69.07M | 67.68M |
Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022
Genetron Holdings Limited's (GTH) CEO Sizhen Wang on Q4 2021 Results - Earnings Call Transcript
Arima Genomics Closes Series B Financing to Support Growing Portfolio of 3D Genomics Solutions for Biomedical Research and Translational Applications
Genetron Health to Announce Fourth Quarter and Full Year 2021 Unaudited Financial Results and Host Investor Call on March 29, 2022
Genetron Health to Participate in Upcoming Investor Conferences
Genetron Holdings Limited (GTH) CEO Sizhen Wang On Q3 2021 Results - Earnings Call Transcript
Genetron Health and IMPACT Therapeutics Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline
Genetron Health Unveils 13 Cancer Research findings at ESMO Congress 2021
Genetron Added to FTSE Russell Global Equity Index Series
Genetron Health's Co-Founder and Chief Scientific Officer Awarded International Prize for Translational Neuroscience 2021
Source: https://incomestatements.info
Category: Stock Reports